Top Page
PuraPharm Corp. Ltd.
(1498)
PuraPharm Corp. Ltd. (1498) vs. iShares MSCI Hong Kong ETF (EWH)
PuraPharm Corp. Ltd. Business Overview & Revenue Model
PuraPharm Corp. Ltd. Financial Statement Overview
| Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 382.09M | 406.86M | 448.07M | 659.59M | 601.82M |
| Gross Profit | 205.14M | 216.63M | 260.59M | 421.85M | 368.69M |
| EBITDA | 17.35M | -26.17M | -46.34M | -40.03M | 114.67M |
| Net Income | -35.44M | -106.08M | -120.21M | -121.88M | 31.71M |
Balance Sheet | |||||
| Total Assets | 715.73M | 843.96M | 1.02B | 1.21B | 1.37B |
| Cash, Cash Equivalents and Short-Term Investments | 12.79M | 47.22M | 107.01M | 85.05M | 126.46M |
| Total Debt | 363.76M | 424.77M | 503.16M | 531.96M | 524.11M |
| Total Liabilities | 604.53M | 690.73M | 757.18M | 803.13M | 859.07M |
| Stockholders Equity | 111.20M | 153.24M | 258.29M | 401.56M | 511.66M |
Cash Flow | |||||
| Free Cash Flow | 89.18M | 57.95M | 42.29M | -45.89M | 3.84M |
| Operating Cash Flow | 103.98M | 79.61M | 65.85M | -39.33M | 86.68M |
| Investing Cash Flow | -11.71M | -18.20M | -25.45M | -3.67M | -82.17M |
| Financing Cash Flow | -86.43M | -122.39M | -12.94M | 8.77M | 29.56M |
PuraPharm Corp. Ltd. Technical Analysis
PuraPharm Corp. Ltd. Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
61 Neutral | HK$296.36M | 1.32 | 23.02% | ― | -6.21% | ― | |
51 Neutral | $7.82B | -0.16 | -39.78% | 2.19% | 21.38% | -1.56% | |
50 Neutral | HK$525.91M | ― | ― | ― | ― | ||
48 Neutral | HK$190.18M | ― | -8.71% | ― | 2.54% | 33.33% | |
45 Neutral | HK$179.70M | ― | -26.80% | ― | -6.09% | 66.59% | |
44 Neutral | HK$264.68M | ― | -40.39% | ― | -43.73% | -434.56% | |
36 Underperform | HK$161.78M | ― | -7.42% | ― | 10.93% | -159.62% |
PuraPharm Corp. Ltd. Corporate Events
PuraPharm Corporation Limited has entered into a Patent Licence Agreement with a licensor, granting them an exclusive non-transferable license for certain intellectual property in exchange for HK$40,200,000 worth of consideration shares. This transaction is considered discloseable and connected due to the involvement of Mr. Chan, a controlling shareholder and executive of the company, and requires approval from independent shareholders. Additionally, PuraPharm has entered into a Subscription Agreement to issue 46,512,000 new shares at HK$0.43 each, raising HK$20,000,160, subject to shareholder approval.
PuraPharm Corporation Limited has issued a profit warning, indicating an expected net loss of approximately HK$24 million for the first half of 2025, compared to a HK$18.7 million loss in the same period of 2024. The anticipated loss is attributed to decreased revenue due to slowed consumption and increased competition in Hong Kong, alongside higher costs of goods sold driven by rising raw material prices and environmental challenges. The interim results are still being finalized and may differ from the preliminary figures.
PuraPharm Corporation Limited announced the resignation of Mr. Ho Kwok Wah, George from his roles as an independent non-executive director and chairman of the audit committee, among other positions, effective July 4, 2025. His departure is due to personal and business commitments, and he has no disagreements with the board. This resignation results in the company not complying with several Hong Kong Stock Exchange listing rules, including the requirement for a minimum number of independent non-executive directors and specific committee compositions.
PuraPharm Corporation Limited has announced the composition of its board of directors and their respective roles within the company. This announcement highlights the leadership structure and committee memberships, which are crucial for the company’s governance and strategic decision-making processes.
PuraPharm Corporation Limited, a company listed on the Hong Kong Stock Exchange, announced the lapse of a disposal agreement related to its accounts receivables. The agreement was not completed due to the short timeframe before the receivables matured, leading to a mutual decision between the seller and purchaser to not proceed. The company stated that this lapse will not have a material impact on its financial position or business operations.
PuraPharm Corporation Limited has announced the appointment of Dr. Kam Biu Tsoi as an executive director effective June 30, 2025. Dr. Tsoi, who has over 40 years of experience in sales management and Chinese medicine, will also join the company’s nomination committee. His appointment is expected to strengthen the company’s leadership in the Chinese medicine sector, given his extensive background and previous association with the company.
PuraPharm Corporation Limited has announced the composition of its board of directors, detailing the roles and functions of each member. This announcement is significant for stakeholders as it outlines the leadership structure and committee memberships, which are crucial for the company’s governance and strategic direction.
PuraPharm Corporation Limited has revised the terms of reference for its Nomination Committee, emphasizing the inclusion of independent non-executive directors and gender diversity among its members. The committee is responsible for overseeing the nomination process, with meetings held at least once a year and resolutions requiring a majority vote to pass. This update reflects the company’s commitment to governance and diversity, potentially enhancing its operational effectiveness and stakeholder confidence.
PuraPharm Corporation Limited announced a discloseable transaction involving the disposal of accounts receivables by its indirect wholly owned subsidiary, Nong’s Company Limited, to Intrabase Financial Services Limited for HK$15,000,000. This transaction, which falls under the Listing Rules due to its applicable percentage ratios, is expected to impact the company’s financials by potentially altering its cash flow and balance sheet. The agreement includes provisions for adjustments based on the actual collection of the receivables, with the company guaranteeing the seller’s obligations.
PuraPharm Corporation Limited announced the successful passing of all proposed resolutions at its annual general meeting held on May 27, 2025. The resolutions included the adoption of financial statements, re-election of directors, re-appointment of the auditor, and granting of mandates to buy back and issue shares. These decisions, unanimously supported by shareholders, reflect strong confidence in the company’s governance and strategic direction.